Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024: Insights On 10 Current & Potential Proprietary Platforms, Company, Indication & Phase for 15 Drugs, and 14 Companies - ResearchAndMarkets.com
The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
- The "Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024" report has been added to ResearchAndMarkets.com's offering.
- Global DLL3 Targeted Therapies Market Opportunities & Clinical Trials Insight 2024 Report Finding & Highlights:
Insight On Current & Potential DLL3 Targeted Therapies Proprietary Platforms: > 10 Platform
DLL3 Targeted Drugs Clinical Trials Insight By Company, Indication & Phase: > 15 Drugs
Insight On Companies Involved In R&D Of DLL3 Targeted Therapies: 14 Companies
In recent years, the discovery of Delta Like Ligand 3 (DLL3) as a therapeutic cancer target has emerged as key defining moment in the targeted therapy landscape. - Stemcentrx, now a subsidiary of AbbVie, led the development of Rovalpituzumab tesirine (Rova-T), which was a pioneering endeavor in the field of DLL3 targeted therapies.
- The dynamic evolution of DLL3 targeted therapies is characterized by a wide range of candidates in clinical trials, extending far beyond Rovalpituzumab conjugates.